Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
Joint Authors
Kimoto, Kenichi
Kubota, Toshiaki
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-11-03
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
We review articles describing intravitreal injection of anti-VEGF drug trials, while discussing the mechanisms of the action of anti-VEGF antibodies, and also evaluating their outcomes.
Intraocular injections of anti-VEGF drug are considered to be an effective treatment for macular edema after retinal vein occlusion, however, recurrent/persistent edema is common.
The recent reports may lead to a shift in treatment paradigm for DME, from laser photocoagulation, to newer approaches using anti-VEGF drugs.
There have been several well-publicized prospective, randomized studies that demonstrated the efficacy of intravitreal injection of anti-VEGF drugs for patients with AMD.
Adjuvant bevacizumab for neovascular glaucoma may prevent further PAS formation, and it is likely to open up a therapeutic window for a panretinal photocoagulation and trabeculectomy.
Intravitreal injection of bevacizumab (IVB) results in a substantial decrease in bleeding from the retinal vessels or new vessels during a standard vitrectomy.
IVB has also been reported to be effective for inducing the regression of new vessels in proliferative diabetic retinopathy.
The use of bevacizumab in stage 4 or 5 retinopahty of permaturity (ROP) is to reduce the plus sign to help reduce hemorrhage during the subsequent vitrectomy.
Some authors reported cases of resolution of stage 4 A ROP after bevacizumab injection.
American Psychological Association (APA)
Kimoto, Kenichi& Kubota, Toshiaki. 2011. Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. Journal of Ophthalmology،Vol. 2012, no. 2012, pp.1-11.
https://search.emarefa.net/detail/BIM-503394
Modern Language Association (MLA)
Kimoto, Kenichi& Kubota, Toshiaki. Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. Journal of Ophthalmology No. 2012 (2012), pp.1-11.
https://search.emarefa.net/detail/BIM-503394
American Medical Association (AMA)
Kimoto, Kenichi& Kubota, Toshiaki. Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. Journal of Ophthalmology. 2011. Vol. 2012, no. 2012, pp.1-11.
https://search.emarefa.net/detail/BIM-503394
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-503394